UMGCCC Clinical Trials

  • More About Clinical Trials
  • Deciding to Enroll
  • Questions to Ask
  • For More Information
  • Research
  • Cancer Overviews
  • Treatment Programs
  • Physicians and Staff
Protocol SummaryBack To Search Instructions
Protocol No.1533GCCPrincipal InvestigatorRao, Gautam
PhasePhase II (Cancer Control)
Age GroupAdult
TitleA Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
DescriptionThis study will only include subjects who have platinum sensitive relapsed epithelial ovarian cancer [meaning your ovarian cancer did not return for at least 6 months after your first treatment with chemotherapy containing platinum (carboplatin or cisplatin)]. CA125 is a protein that is found in the blood of most ovarian cancer subjects. Subjects will only be included in this study if their CA125 test result does not exceed a certain level.
TreatmentCarboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), given with an investigational drug called farletuzumab or a placebo.
Key EligibilityPlease refer to for more information Identifier: NCT02289950
Applicable Disease SitesOvary
Therapies InvolvedChemotherapy (NOS)
Chemotherapy multiple agents systemic
Drugs InvolvedMORab-003 (Farletuzumab)
doxorubicin pegylated liposome (PLD)
Treatment TypeTreatment
ContactGreenebaum Cancer Center Maha Khalil, PhD Phone:410-328-5009
Back to Protocol Listing